Lower blood-thinner dose after heart attack for high bleeding risk
Part of Heart & circulation clinical trials.
This Phase 4 study tests whether using a reduced blood-thinner (antithrombotic) strategy after a heart attack can lower bleeding without losing heart protection. It is mainly for people considered high risk for bleeding after getting a stent.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your heart attack was a type caused by a blocked heart artery (Type 1 MI) and you had a stent placed (drug-eluting stent) using PCI
- Your bleeding risk score (PRECISE-DAPT) is 25 or higher
- You can take aspirin and a P2Y12 blood thinner (and you’re not allergic to them)
- You do NOT need long-term blood thinners taken by mouth for another reason
- You don’t have current active bleeding or a history of bleeding in the brain
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter, lower dose of two blood thinners is safe and effective for patients with a recent heart attack or unstable angina who are at high risk for bleeding. It uses a special stent that might allow for less medication.
This study tests whether a personalized score (OPT-CAD) can help decide the best time to stop or reduce blood-thinning medication in people who have had a heart attack and a stent placed. It aims to balance preventing future heart issues while lowering the risk of bleeding.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This trial tests if a very short course of dual antiplatelet therapy (two blood thinners) after getting a stent is safe and effective for patients aged 65 and older. The goal is to reduce bleeding risks while still preventing heart attacks.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
Hear when a new Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.